Medtronic Drug-Eluting Stent Revenue Up 42%

Medtronic, Inc. (NYSE: MDT) today announced financial results for the third quarter of fiscal year 2013, which ended January 25, 2013. One of fastest growing segments of this $4 billion company was the coronary division which grew 19% overall. Fueled by sales of its Resolute Integrity Zotarolimus-eluting stent, approved last year in the U.S. and Japan, drug-eluting stent quarterly revenue was up 42% to $274 million.

Source: News from Angioplasty.Org - February 19, 2013 Category: Cardiology Source Type: news